The off-label use of targeted therapies in sarcomas: The OUTC'S program

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Eberst, Lauriane ^a,b   Cropet, Claire ^a   Le Cesne, Axel ^c   Pautier, Patricia ^c   Penel, Nicolas ^d   Adenis, Antoine ^d   Chevreau, Christine ^e   Bay, Jacques Olivier ^f,g   Collard, Olivier ^h   Cupissol, Didier ⁱ   Duffaud, Florence ^j   Gentet, Jean Claude ^j   Piperno Neumann, Sophie ^k   Marec Berard, Perrine ^a   Bompas, Emmanuelle ^l   Thyss, Antoine ^m   Chaigneau, Loic ⁿ   Cassier, Philippe ^a   Bertucci, François ^o   Blay, Jean Yves ^a,b   Ray Coquard, Isabelle ^a,b   more..

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f CENTRE JEAN PERRIN   (France)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h Lucien Neuwirth Cancer Institute   (France)

ⁱ Regional Cancer Institute   (France)

^j TIMONE HOSPITAL   (France)

^k INSTITUT CURIE   (France)

^l CENTRE RENÉ GAUDUCHEAU   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^o INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

Off label; Register; Sarcoma; Targeted therapy; Tumor board

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACARBAZINE; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; IMATINIB; MASITINIB; METFORMIN; NILOTINIB; PACLITAXEL; PANOBINOSTAT; PAZOPANIB; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ZOLEDRONIC ACID; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER SURVIVAL; CHONDROSARCOMA; CHORDOMA; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTOSARCOMA PHYLLOIDES; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM SARCOMA; EPITHELIOID SARCOMA; EWING SARCOMA; FEMALE; FIBROMATOSIS; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEALTH PROGRAM; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION; KAPOSI SARCOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROLOGIC DISEASE; OFF LABEL DRUG USE; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIVASCULAR EPITHELIOID CELL TUMOR; PROGRESSION FREE SURVIVAL; SARCOMA; SKIN TOXICITY; SOLITARY FIBROUS TUMOR; STOMATITIS; SURVIVAL RATE; SYNOVIAL SARCOMA; TREATMENT RESPONSE; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; MIDDLE AGED; PATHOLOGY; REGISTER; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NIACINAMIDE; OFF-LABEL USE; PHENYLUREA COMPOUNDS; PYRROLES; REGISTRIES; SARCOMA; SIROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924345871     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-870     Document Type: Article

References (43)

1. Clark MA, Fisher C, Judson I, Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med 2005, 353:701-711. 10.1056/NEJMra041866.
2. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere A-V, Péoc'h M, Istier L, Chalabreysse P, Muller C, Alberti L, Bringuier P-P, Scoazec J-Y, Schott A-M, Bergeron C, Cellier D, Blay J-Y, Ray-Coquard I: Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE 2011, 6:e20294. 10.1371/journal.pone.0020294.
3. Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, Michels J-J, Blay J-Y, Coindre J-M, Bui B: Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011, 117:1049-1054. 10.1002/cncr.25538.
4. Lurkin A, Ducimetière F, Vince DR, Decouvelaere A-V, Cellier D, Gilly FN, Salameire D, Biron P, de Laroche G, Blay JY, Ray-Coquard I: Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer 2010, 10:150. 10.1186/1471-2407-10-150.
5. Wardelmann E, Schildhaus H-U, Merkelbach-Bruse S, Hartmann W, Reichardt P, Hohenberger P, Büttner R: Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol 2010, 21 Suppl 7:vii265-vii269.
6. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS-J, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004, 22:1706-1712. 10.1200/JCO.2004.08.043.
7. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007, 25:2755-2763. 10.1200/JCO.2006.10.4117.
8. Bay J-O, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre J-M, Bui NB, Peyrade F, Penel N, Blay J-Y: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006, 119:706-711. 10.1002/ijc.21867.
9. García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM: Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011, 29:2528-2533. 10.1200/JCO.2010.33.6107.
10. ESMO Clinical Practice Guidelines - European Society for Medical Oncology (ESMO). [http://www.esmo.org/education-research/esmo-clinical-practice-guidelines.html#c3345]
11. NCCN Clinical Practice Guidelines in Oncology. [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#sarcoma]
12. Antonescu CR: The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011, 223:251-261.
13. Judson I: Targeted therapies in soft tissue sarcomas. Ann Oncol 2010, 21 Suppl 7:vii277-vii280.
14. Romeo S, Dei Tos AP: Clinical application of molecular pathology in sarcomas. Curr Opin Oncol 2011, 23:379-384. 10.1097/CCO.0b013e328347b9be.
15. Simon MP, Navarro M, Roux D, Pouysségur J: Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP). Oncogene 2001, 20:2965-2975. 10.1038/sj.onc.1204426.
16. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM: European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1779. 10.1200/JCO.2009.25.7899.
17. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, van der Graaf WT, Italiano A, Seddon B, Dômont J, Bompas E, Wagner AJ, Blay J-Y: Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012, 118:1649-1655. 10.1002/cncr.26409.
18. Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, Jimenez M, Duffaud F, Piperno-Neumann S, Mignot L, Blay J-Y: Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011, 22:452-457. 10.1093/annonc/mdq341.
19. Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH: Sarcoma Alliance for Research through Collaboration (SARC): Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010, 16:4884-4891. 10.1158/1078-0432.CCR-10-1177.
20. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S: Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280. 10.1016/S1470-2045(10)70010-3.
21. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Myers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009, 27:3148-3153. 10.1200/JCO.2008.20.5054.
22. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin L-X, Antonescu CR, Schwartz GK: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009, 27:3133-3140. 10.1200/JCO.2008.20.4495.
23. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009, 27:3154-3160. 10.1200/JCO.2008.20.9890.
24. Van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886. 10.1016/S0140-6736(12)60651-5.
25. Blay J-Y, Chawla SP, Ray-Coquard I, Cesne AL, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing DA, Song Y, Ebbinghaus S, Haluska FG, Dodion PF, Demetri GD: Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (> = 24 months) overall survival results. ASCO Meeting Abstracts 2012, 30:10010.
26. Leahy M, Garcia Del Muro X, Reichardt P, Judson I, Staddon A, Verweij J, Baffoe-Bonnie A, Jönsson L, Musayev A, Justo N, Burke T, Blay JY: Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann Oncol 2012.
27. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010, 70:7610-7619. 10.1158/0008-5472.CAN-09-4272.
28. Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T, Fushiki S: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 2007, 96:255-261. 10.1038/sj.bjc.6603548.
29. NetSarc - Accueil. [https://www.netsarc.org/home.htm]
30. Imaging Response Criteria - Cancer Imaging Program - National Cancer Institute. [http://imaging.cancer.gov/clinicaltrials/imaging]
31. CTCAE Files. [http://evs.nci.nih.gov/ftp1/CTCAE/About.html]
32. Nystrom LM, Reimer NB, Reith JD, Dang L, Zlotecki RA, Scarborough MT, Gibbs CP: Multidisciplinary management of soft tissue sarcoma. Sci World J 2013, 2013:852462.
33. Van Glabbeke M, Verweij J, Judson I: Nielsen OS, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549. 10.1016/S0959-8049(01)00398-7.
34. Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A: Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 2011, 129:1963-1969. 10.1002/ijc.25843.
35. Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE: Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. ASCO Meeting Abstracts 2011, 29:10009.
36. Cassier PA, Labidi-Galy SI, Heudel P, Dutour A, Méeus P, Chelghoum M, Alberti L, Ray-Coquard I, Blay J-Y: Therapeutic pipeline for soft-tissue sarcoma. Expert Opin Pharmacother 2011, 12:2479-2491. 10.1517/14656566.2011.604633.
37. Olmos D, Tan DSW, Jones RL, Judson IR: Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010, 16:183-194. 10.1097/PPO.0b013e3181dbebf9.
38. Kenerson H, Folpe AL, Takayama TK, Yeung RS: Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 2007, 38:1361-1371. 10.1016/j.humpath.2007.01.028.
39. Italiano A, Delcambre C, Hostein I, Cazeau AL, Marty M, Avril A, Coindre J-M, Bui B: Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010, 21:1135-1137. 10.1093/annonc/mdq044.
40. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CDM, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG: Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010, 28:835-840. 10.1200/JCO.2009.25.2981.
41. Subbiah V, Trent JC, Kurzrock R: Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol 2010, 28:e415. 10.1200/JCO.2010.29.4678.
42. Cassier P, Tredan O, Seigne C, Lavergne E, Fayette J, Desseigne F, Biron P, De La Fouchardiere C, Ray-Coquard IL, Perol M, Frappaz D, Bernardin M, Wang Q, Attignon V, Pissaloux D, Combaret V, Agrapart V, Fondrevelle M-E, Perol D, Blay J-Y: Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program. ASCO Meeting Abstracts 2014, 32:2621.
43. Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord J-P, Campone M, Goncalves A, Isambert N, et al.: Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014, 111:17-24. 10.1038/bjc.2014.211.